DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable

od Fleischmann, Roy M, van der Heijde, Désirée, Gardiner, Philip V, Szumski, Annette, Marshall, Lisa, Bananis, Eustratios
Izdano u RMD Open (2017)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoi...

od Kavanaugh, Arthur, Fleischmann, Roy M, Emery, Paul, Kupper, Hartmut, Redden, Laura, Guerette, Benoit, Santra, Sourav, Smolen, Josef S
Izdano 2013

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a...

od Fleischmann, Roy M, Alvarez, Daniel F, Bock, Amy E, Cronenberger, Carol, Vranic, Ivana, Zhang, Wuyan, Alten, Rieke
Izdano u RMD Open (2021)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

od Burmester, Gerd-Rűdiger, Kivitz, Alan J, Kupper, Hartmut, Arulmani, Udayasankar, Florentinus, Stefan, Goss, Sandra L, Rathmann, Suchitrita S, Fleischmann, Roy M
Izdano u Ann Rheum Dis (2015)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis

od Fleischmann, Roy M, Huizinga, Tom W J, Kavanaugh, Arthur F, Wilkinson, Bethanie, Kwok, Kenneth, DeMasi, Ryan, van Vollenhoven, Ronald F
Izdano u RMD Open (2016)

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

od Pope, Janet, Bingham, Clifton O., Fleischmann, Roy M., Dougados, Maxime, Massarotti, Elena M., Wollenhaupt, Jürgen, Duncan, Benjamin, Coteur, Geoffroy, Weinblatt, Michael E.
Izdano u Arthritis Res Ther (2015)

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

od Kirkham, Bruce W, Wasko, Mary Chester, Hsia, Elizabeth C, Fleischmann, Roy M, Genovese, Mark C, Matteson, Eric L, Liu, Hongjuan, Rahman, Mahboob U
Izdano 2014

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insuf...

od Fleischmann, Roy M, Genovese, Mark C, Enejosa, Jeffrey V, Mysler, Eduardo, Bessette, Louis, Peterfy, Charles, Durez, Patrick, Ostor, Andrew, Li, Yihan, Song, In-Ho
Izdano u Ann Rheum Dis (2019)

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

od van Vollenhoven, Ronald F, Emery, Paul, Bingham, Clifton O, Keystone, Edward C, Fleischmann, Roy M, Furst, Daniel E, Tyson, Nicola, Collinson, Neil, Lehane, Patricia B
Izdano 2013

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the r...

od Huizinga, Tom W J, Fleischmann, Roy M, Jasson, Martine, Radin, Allen R, van Adelsberg, Janet, Fiore, Stefano, Huang, Xiaohong, Yancopoulos, George D, Stahl, Neil, Genovese, Mark C
Izdano 2014

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

od Stohl, William, Gomez-Reino, Juan, Olech, Ewa, Dudler, Jean, Fleischmann, Roy M, Zerbini, Cristiano A F, Ashrafzadeh, Ali, Grzeschik, Susanna, Bieraugel, Rebecca, Green, Jennifer, Francom, Steven, Dummer, Wolfgang
Izdano 2012

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

od Fleischmann, Roy M, Blanco, Ricardo, Hall, Stephen, Thomson, Glen T D, Van den Bosch, Filip E, Zerbini, Cristiano, Bessette, Louis, Enejosa, Jeffrey, Li, Yihan, Song, Yanna, DeMasi, Ryan, Song, In-Ho
Izdano u Ann Rheum Dis (2021)

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

od Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia
Izdano u Rheumatology (Oxford) (2020)

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial

od Emery, Paul, Fleischmann, Roy M., Strusberg, Ingrid, Durez, Patrick, Nash, Peter, Amante, Eric Jason B., Churchill, Melvin, Park, Won, Pons‐Estel, Bernardo, Han, Chenglong, Gathany, Timothy A., Xu, Stephen, Zhou, Yiying, Leu, Jocelyn H., Hsia, Elizabeth C.
Izdano u Arthritis Care Res (Hoboken) (2016)

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand os...

od Kloppenburg, Margreet, Peterfy, Charles, Haugen, Ida K, Kroon, Féline, Chen, Su, Wang, Li, Liu, Wei, Levy, Gwen, Fleischmann, Roy M, Berenbaum, Francis, van der Heijde, Désirée, Bansal, Prashant, Wittoek, Ruth, Feng, Sheng, Fang, Yuni, Saltarelli, Mary, Medema, Jeroen K, Levesque, Marc C
Izdano u Ann Rheum Dis (2019)

Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

od Zanin-Zhorov, Alexandra, Weiss, Jonathan M., Trzeciak, Alissa, Chen, Wei, Zhang, Jingya, Nyuydzefe, Melanie S., Arencibia, Carmen, Polimera, Seetharam, Schueller, Olivier, Fuentes-Duculan, Judilyn, Bonifacio, Kathleen M., Kunjravia, Norma, Cueto, Inna, Soung, Jennifer, Fleischmann, Roy M., Kivitz, Alan, Lebwohl, Mark, Nunez, Margarita, Woodson, Johnnie, Smith, Shondra L., West, Robert F., Berger, Mark, Krueger, James G., Ryan, John L., Waksal, Samuel D.
Izdano u J Immunol (2017)

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

od Nash, Peter, Kerschbaumer, Andreas, Dörner, Thomas, Dougados, Maxime, Fleischmann, Roy M, Geissler, Klaus, McInnes, Iain, Pope, Janet E, van der Heijde, Désirée, Stoffer-Marx, Michaela, Takeuchi, Tsutomu, Trauner, Michael, Winthrop, Kevin L, de Wit, Maarten, Aletaha, Daniel, Baraliakos, Xenofon, Boehncke, Wolf-Henning, Emery, Paul, Isaacs, John D, Kremer, Joel, Lee, Eun Bong, Maksymowych, Walter P, Voshaar, Marieke, Tam, Lai-Shan, Tanaka, Yoshiya, van den Bosch, Filip, Westhovens, René, Xavier, Ricardo, Smolen, Josef S
Izdano u Ann Rheum Dis (2021)